Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria ...

ASCEND was a multicenter, placebo-controlled trial that aimed to investigate the effects of the endothelin-A (ET A) receptor antagonist avosentan in patients with diabetic nephropathy. The study ...

Michael Moye, President and General Manager of Idorsia US, commented: “The fact that the FDA has expedited the approval of the updated TRYVIO label to remove the REMS requirements is, I believe, a ...

The approval is supported by a prespecified interim analysis from the ongoing, randomised Phase III ALIGN trial.

The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...